Literature DB >> 30195742

Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses.

Felice Iasevoli1, Camilla Avagliano1, Benedetta Altavilla1, Annarita Barone1, Mariateresa Ciccarelli1, Luigi D'Ambrosio1, Danilo Notar Francesco1, Eugenio Razzino1, Michele Fornaro1, Andrea de Bartolomeis2.   

Abstract

Here, we used Receiver Operating Characteristic (ROC) curve analysis to determine whether clinical factors may aid predicting the categorization of schizophrenia patients as Treatment Resistant (TRS) or antipsychotic responsive schizophrenia (ARS). Patients with an established condition of TRS or ARS were assessed for: clinical presentation and course; neurological soft signs (NES); psychopathology by PANSS; cognitive performances; quality of life scale (QLS); functional capacity; social functioning (PSP and SLOF scales). In ROC curve analysis, significance indicated that the Area under curve (AUC) allowed distinguishing between TRS and ARS. Multivariate analyses were additionally used to provide independent predictive analysis. Multiple clinical variables showed significant AUCs. The largest significant AUCs were found for: NES total score; SLOF Area2; QLS subscale; antipsychotic doses. The highest sensitivity was found for NES total score, the highest specificity for previous hospitalizations. The highest Odds Ratio of being included within the TRS category were found for: NES total score (7.5); QLS total score (5.49); and previous hospitalizations (4.76). This same circumscribed group of variables was also found to be predictive of TRS when adopting stepwise logistic regression or discriminant analysis. We concluded that the evaluation of few clinical factors may provide reliable and accurate predictions on whether one schizophrenia patient may be categorized as a TRS.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Antipsychotic; Dopamine; Neurological soft signs; Psychosis; Treatment refractory; Treatment resistant schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 30195742     DOI: 10.1016/j.psychres.2018.08.109

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

1.  Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs.

Authors:  Felice Iasevoli; Camilla Avagliano; Benedetta Altavilla; Annarita Barone; Luigi D'Ambrosio; Marta Matrone; Danilo Notar Francesco; Eugenio Razzino; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2018-10-31       Impact factor: 4.157

2.  Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study.

Authors:  Edward Millgate; Eugenia Kravariti; Alice Egerton; Oliver D Howes; Robin M Murray; Laura Kassoumeri; Jacek Donocik; Shôn Lewis; Richard Drake; Stephen Lawrie; Anna Murphy; Tracy Collier; Jane Lees; Charlotte Stockton-Powdrell; James Walters; Bill Deakin; James MacCabe
Journal:  BMJ Open       Date:  2021-11-25       Impact factor: 2.692

3.  A predictor model of treatment resistance in schizophrenia using data from electronic health records.

Authors:  Giouliana Kadra-Scalzo; Daniela Fonseca de Freitas; Deborah Agbedjro; Emma Francis; Isobel Ridler; Megan Pritchard; Hitesh Shetty; Aviv Segev; Cecilia Casetta; Sophie E Smart; Anna Morris; Johnny Downs; Søren Rahn Christensen; Nikolaj Bak; Bruce J Kinon; Daniel Stahl; Richard D Hayes; James H MacCabe
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

4.  Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.

Authors:  Felice Iasevoli; Eugenio Razzino; Benedetta Altavilla; Camilla Avagliano; Annarita Barone; Mariateresa Ciccarelli; Luigi D'Ambrosio; Marta Matrone; Federica Milandri; Danilo Notar Francesco; Michele Fornaro; Andrea de Bartolomeis
Journal:  Early Interv Psychiatry       Date:  2021-05-16       Impact factor: 2.721

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.